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Abstract
CRISPR-Cas systems constitute adaptive immune systems for antiviral defense in bacteria.
We investigated the occurrence and diversity of CRISPR-Cas systems in 48 Bifidobacter-
ium genomes to gain insights into the diversity and co-evolution of CRISPR-Cas systems
within the genus and investigate CRISPR spacer content. We identified the elements nec-
essary for the successful targeting and inference of foreign DNA in select Type II CRISPR-
Cas systems, including the tracrRNA and target PAM sequence. Bifidobacterium species
have a very high frequency of CRISPR-Cas occurrence (77%, 37 of 48). We found that
many Bifidobacterium species have unusually large and diverse CRISPR-Cas systems
that contain spacer sequences showing homology to foreign genetic elements like pro-
phages. A large number of CRISPR spacers in bifidobacteria show perfect homology to
prophage sequences harbored in the chromosomes of other species of Bifidobacterium,
including some spacers that self-target the chromosome. A correlation was observed
between strains that lacked CRISPR-Cas systems and the number of times prophages in
that chromosome were targeted by other CRISPR spacers. The presence of prophage-tar-
geting CRISPR spacers and prophage content may shed light on evolutionary processes
and strain divergence. Finally, elements of Type II CRISPR-Cas systems, including the
tracrRNA and crRNAs, set the stage for the development of genome editing and genetic
engineering tools.
Introduction
Clustered regularly interspaced short palindromic repeats (CRISPR) with CRISPR-associated
(cas) genes constitute the CRISPR-Cas adaptive immune systems in bacteria and archaea [1].
CRISPR loci are identified in genomes by locating regions of conserved repeats interspersed by
short variable sequences, spacers, that are adjacent to cas genes. The immune function of the
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systems is carried out by Cas proteins in three steps: first, the acquisition of DNA from an
invader is stored between conserved repeats; next, the entire repeat-spacer array is transcribed
into a single RNA transcript that must be processed into individual small interfering units dur-
ing the expression phase; and finally, during interference, the guide RNA direct Cas proteins to
its target and cleaves foreign invaders in a highly sequence-specific manner upon reinfection
[2–6]. Repeat-spacer arrays record the immunization timeline of an organism as spacer
sequences, which are always added to the array at the leader end; this can provide a unique,
hypervariable locus that can be used to genotype organisms so as to provide insights into their
phylogenetic divergence and relatedness to other strains [7]. Identifying the source of the
spacer sequences, called the protospacer sequence, can tell a story of host-prey dynamics in
environments where phage and plasmid intrusions are common and often lethal [8]. Several
early CRISPR metagenomic and ecological studies have investigated the co-evolutionary effects
of phage predation and CRISPR-acquired defense on both the host bacterium and predatory
mobile genetic material [8–12]. Iterative phage infection and consequent mutations to escape
CRISPR targeting drive phage genome evolution as well as host strain evolution through adap-
tation and acquisition of new immunity-conferring spacers at CRISPR loci [1,8–12].
Three types of CRISPR-Cas systems with distinct locus architecture and Cas effector pro-
teins have been described [13]. While all have the universal cas1 gene, each main type has a sig-
nature gene used to classify CRISPR loci into types: cas3 for Type I, cas9 for Type II, and cas10
for Type III. Type I and Type III systems carry out the interference stage of immunity using a
large CRISPR associated complex for anti-viral defense (Cascade) protein complex composed
of several Cas protein subunits [3,5]. In contrast, Type II systems only require a single endonu-
clease, Cas9, to effectively target and cleave foreign DNA [14–16]. In all three systems, RNA
molecules, called CRISPR RNAs (crRNAs), that contain a partial CRIPSR repeat and partial
spacer guide the Cas proteins to their DNA targets. In Type I systems, there is only a single
crRNA to direct the CASCADE complex, while Type II systems require an additional trans-
activating CRISPR RNA (tracrRNA) bound to the crRNA to form a crRNA:tracrRNA duplex
[2–6]. Recently, the Cas9 machinery has been developed into a sequence-specific DNA-target-
ing and cleaving tool through re-programming of the native protein and crRNA:tracrRNA
duplex, revolutionizing genetic engineering [17–19].
Bifidobacteria have become increasingly studied as their potential to positively affect human
host health becomes better characterized [20–21]. Through their interactions with the human
gastrointestinal tract (GIT), bifidobacteria may help fortify the intestinal barrier, modulate
immune responses, and competitively exclude pathogens [20–21]. Bifidobacteria have charac-
teristically small genomes ranging in size from 2.0 to 2.8 Mbp [22]; the small size of bifidobac-
terial genomes is hypothesized to be caused by genome decay as dispensable genes are lost
driving adaption to a specific ecological niche [23–24]. While many intra-species studies have
thoroughly investigated genomic differences within single species like Bifidobacterium animalis
[25], Bifidobacterium dentium [26], Bifidobacterium bifidum [27],as well as Bifidobacterium
breve and Bifidobacterium longum [28], only a few studies have investigated differentiating fea-
tures of species across the genus [23, 29].
While bifidobacterial genomes have been studied fairly extensively, little research has
focused on elucidating the role that parasitic phages and prophages have played in shaping
the fitness of different Bifidobacterium species. Previous work by Ventura et al. investigated
the prevalence of prophages in bifidobacteria and was the first study to propose that the inter-
play between bifidobacteria and phages drives coevolution of both the phage and host as
evidenced by the prevalence of prophages and CRISPR-Cas systems [20,30]. Overall, 22 pro-
phage-like elements have been characterized in the genus Bifidobacterium, occurring in nine
strains representing six species that include: B. dentium, B longum, B. bifidum B. animalis and
CRISPR and Bifidobacteria
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Bifidobacterium adolescentis [20, 30–31]. Several studies have suggested that prophages in bifi-
dobacteria are a major source of lateral gene transfer and driver of population adaptation to
environmental niches [20, 30–31]. Prophage integration is a proposed mechanism for host
adaptation as some prophage-elements include genes for increased host viability like polyketide
biosynthesis, type I restriction modification systems, and retro-type reverse transcriptase [20].
In this study, we aimed to investigate the prevalence and diversity of CRISPR-Cas systems
in 48 Bifidobacterium genomes in an attempt to gain insights into the phylogenetic history and
biological importance of these systems. First, we identified and characterized repeat-spacer
arrays and cas genes. Next, we compared the different systems using conserved elements to
look for system relatedness and divergence. Spacers were further analyzed to identify homology
to foreign DNA sequences in genomic and metagenomic data to determine potential functional
roles these immune systems might play. Further characterization of Type II CRISPR-Cas sys-
tems were performed to identify elements necessary for interference, including the non-coding
tracrRNA and target PAM sequence, for select systems.
Materials and Methods
In silico analyses
The genomes used were previously described by Milani et al. [19] (Table 1). CRISPR analyses
were performed using CRISPRfinder followed by manual curation to identify and assemble
repeat-spacer arrays [32]. BLAST [33] was used to identify Cas proteins and confirm subtype
designation [13]. SnapGene (GSL Biotech) was used to annotate cas genes and generate the
operon layout. The Cas1 alignment was performed using the MUSCLE alignment algorithm;
the consensus tree was constructed in MEGA version 6 [34] using the UPGMA Jukes-Cantor
model calculating bootstrap values with 500 samples. Protospacers were identified using
BLASTn against publically available metagenomic datasets and a locally created bifidobacter-
ium database. A “strong” protospacer match was considered when two examined sequences
exhibited more than 90% identity over 90% of the spacer sequence length. Additional analyses
were performed to detect similarity between CRISPR spacers and prophage sequences located
within the bifidobacterium genomes used in this study. Once potential protospacers were iden-
tified, the flanking regions were aligned by hand and analyzed by WebLogo to determine the
protospacer adjacent motif (PAM) [35]. The tracrRNA sequences for Bifidobacterium bombi,
Bifidobacterium merycicum, and B. bifidum were predicted manually using BLAST to identify
anti-repeat region in the respective genomes per the modules previously defined by Briner
et al. [36]. NUPACK was used to generate RNA folding prediction images [37].
Table 1 | Occurrence of CRISPR-Cas systems in bifidobacteria | Each strain used in this
analysis was examined for CRISPR-Cas systems. “System Type” refers to the type and subtype
of the predicted system. The sequence, repeat length, and number of repeats found in a single
repeat-spacer array are given for each system. When repeat-spacer arrays were detected but no
cas genes were annotated, the system type was designated “Undetermined.” “None” indicates
that repeat-spacer arrays and cas genes were not found in the genome. Cas indicated the pres-
ence or absence of cas genes, with a “Y” indicating the gene is present and an “N” indicating
the gene is absent. Type designation was confirmed by the presence of cas3, cas9, and cas10 for
Type I, II, and III respectively.
CRISPR and Bifidobacteria
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Table 1. Occurrence of CRISPR-Cas systems in bifidobacteria.
Biﬁdobacterium Species Strain System Type CRISPR Repeat Sequence RepeatLength Numberof
Repeats
cas1 cas3 cas9 cas10
B. actinocoloniiforme DSM
22766
I-E GTGTTCCCCGCATGCGCGGGGATGATCCC 29 81 Y Y
B. adolescentis ATCC
15703
I-C GTCGCTCTCCTTACGGAGAGCATGGATTGAAAT 33 86 Y Y
B. angulatum LMG
11039
I-E GTGTTCCCCGCACACGCGGGGATGATCCC 29 172 Y Y
B. animalis subsp. animalis ATCC
25527
I-E GTTTGCCCCGCACAGGCGGGGATGATCCG 29 32 Y Y
B. animalis subsp. lactis DSM
10140
I-U ATCTCCGAAGTCTCGGCTTCGGAGCTTCATTGAGGG 36 19 Y Y
B. asteroides PRL2011 I-E GTGTTCCCCGCATCCGCGGGGATGATCC 28 147 Y Y
B. biavatii DSM
23969
None none
B. biﬁdum LMG
13200
II-A GTTTCAGATGCCTGTCAGATCAATGACTTTGACCAC 36 23 Y Y
B. bohemicum DSM
22767
I-C GTCGCTCCCTTCACAGGGAGCGTGGATTGAAAT 33 20 Y Y
B. bombi DSM
19703
II-C CCAGTATATCAGAGGGGCTTTAGATTGAATTTGAAAC 37 25 Y Y
B. boum LMG
10736
I-E GTGTTCCCCGCGCATGCGGGGATGATCCC 29 157 Y Y
B. breve UCC2003 I-C GTCGATCCCCATCCGGGGAGCGTGGATTGAAAT 33 48 Y Y
B. callitrichos DSM
23973
II-C CAAGTCTATCAAGAAGGGTGAATGCTAATTCCCAAC 36 13 Y Y
B. catenulatum DSM
16992
I-E GTGTTCCCCGCATACGCGGGGATGATCCC 29 15 Y Y
B. choerinum LMG
10510
Undetermined GTGCTCCTCGCAAGCGCGTGGACAACCCG 29 20 N
B. coryneforme LMG
18911
None none
B. crudilactis LMG
23609
I-C GTCGCTCCCTCACGGGAGCGTGGATTGAAAT 31 36 Y Y
B. cuniculi LMG
10738
I-E AGTTGCCCCGCGTATGCGGGGATGATCCG 29 93 Y Y
B. dentium LMG
11045
II-C CAAGTTTATCAAGAAGGGTAGAAGCTAATTCCCAGT 36 17 Y Y
I-C GTCGCTCTCCTCACGGAGAGCGTGGATTGAAAT 33 81 Y Y
Undetermined TGTCCGATTCTCCAGAATCGGACA 24 8 N
B. gallicum DSM
20093
I-E GTGCTCCCCGCAAGCGCGGGGATGATCC 28 39 Y Y
B. gallinarum LMG
11586
None none
B. indicum LMG
11587
None none
B. kashiwanohense DSM
21854
None none
B. longum subsp. infantis ATCC
15697
None none
B. longum subsp. longum NCC2705 None none
B. longum subsp. suis LMG
21814
Undetermined GTCGCACCCCACTGGGGTGCGTGGATTGAAAT 32 9 N
B. magnum LMG
11591
Undetermined GTGCTCCCCACATAGGTGGGGATGAT 26 4 N
B. merycicum LMG
11341
II-A GTTTCAGATGCCTGTCAGATCAAGGACCTAGACCAC 36 87 Y Y
(Continued)
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Results
Occurrence and diversity of CRISPR-Cas systems in Bifidobacterium
Among the 48 genomes analyzed, we observed a high rate of occurrence of CRISPR-Cas sys-
tems in the genus Bifidobacterium (77%) (Table 1), compared to the estimated prevalence in
bacteria (45%, 1176/2612, as of the August 2014 update) [32]. In the 48 genomes analyzed, rep-
resenting 43 species, we identified 26 Type I systems, and six Type II systems, while Type III
systems appeared to be absent, according to the cas gene content and CRISPR repeat length
and sequence. Interestingly, four strains contained multiple distinct CRISPR-Cas systems,
Table 1. (Continued)
Biﬁdobacterium Species Strain System Type CRISPR Repeat Sequence RepeatLength Numberof
Repeats
cas1 cas3 cas9 cas10
B. minimum LMG
11592
I-E GTTTGCCCCGCACTCGCGGGGATGATCC 29 149 Y Y
B. mongoliense DSM
21395
None none N
B. moukalabense DSM
27321
Undetermined ATTTCAATCCACGCTCTCCGTGAGGAGAGCGAC 33 15 Y
B. pseudocatenulatum DSM
20438
I-C GTCGCTCTCCTCATGGAGAGCGTGGATTGAAAT 33 27 Y Y
B. pseudolongum subsp.
globosum
LMG
11569
None none
B. pseudolongum subsp.
pseudolongum
LMG
11571
I-E GTTTGCCCCGCATGTGCGGGGATGATCCG 29 112 Y Y
B. psychraerophilum LMG
21775
None none
B. pullorum LMG
21816
I-U ATTGCGAAGCTTTACGCTTCGCAACTTCATTGAGGA 36 20 Y Y
B. reuteri DSM
23975
Undetermined CCGAGGTTCCGCCCCGCTGAGGA 23 13 N
B. ruminantium LMG
21811
I-E GTGTTCCCCGCATGCGCGGGGATGATCCC 29 67 Y Y
Undetermined ATGTCCGATTCTGCAGAATCGGACA 25 16 N
B. saeculare LMG
14934
None none
B. saguini DSM
23967
I-C GTCACCCTCCTCACGGAGGGTGCGGATTGAAAT 33 31 Y Y
B. scardovii LMG
21589
I-E GTTTACCCCGCATGCGCGGGGATGATCCG 29 66 Y Y
B. stellenboschense DSM
23968
I-C GTCGCCCCTCTCACGAGGGGCGTGGATTGAAAT 33 51 Y Y
B. stercoris DSM
24849
Undetermined TTGGATGTGAGCGGCTGGAACACC 24 6 N
B. subtile LMG
11597
I-C GTCGCTCCCTCACGGGAGCGTGGATTGAAAT 31 156 Y Y
B. thermacidophilum
subsp. porcinum
LMG
21689
Undetermined TTGTGTGAGGATTTGCTCGCACA 23 5 N
B. thermacidophilum
subsp. thermacidophilum
LMG
21395
I-C ATCGCTCCCCGTATGGGGAGCGTGAGTTGAAAT 33 89 Y Y
B. thermophilum JCM
7027
I-U ATTGCCGGGATTCAATTCCCGGCGCTTCATTGAGGG 36 53 Y Y
Undetermined GTCGCTCTCCTTACGGAGAGCGTGGATTGAAAT 33 11 N
B. tsurumiense JCM
13495T
I-U ATTGCCAGAGTTATAAGCTCTGGCCTTCGTTGAGGA 36 7 Y Y
II-C CAATCTTATCAAGAGGGTAGAAAGCTAATTCACAGC 36 13 Y Y
doi:10.1371/journal.pone.0133661.t001
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including B. dentium which contained three separate systems. Each Bifidobacterium species
containing a CRISPR-Cas system had a unique CRISPR repeat and cas1 gene, suggesting that
these systems are phylogenetically different from one another. Strains that contained repeat-
spacer arrays but did not contain cas genes were categorized as “Undetermined”; given the
repetitive nature of CRISPR loci and the draft genome status of many genomes, there are possi-
bly additional loci that could not be identified or classified. Bifidobacterium moukalabense was
also defined as “undetermined” because it only contained the repeat-spacer array and cas1 and
cas2 genes; no other cas genes were found within this locus. The high rate of occurrence and
occasional presence of multiple systems in a single genome suggests that bifidobacteria possess
active CRISPR immune systems that are important in the defense against potentially damaging
foreign DNA.
A phylogenetic analysis was performed to investigate the level of conservation and diver-
gence between the identified bifidobacterial CRISPR immune systems using the universal Cas1
protein. The Cas1 tree in Fig 1 revealed five major clusters that correspond to different types
and subtypes of CRISPR systems, namely a branch for Type I-E, I-C, I-U, Type II-A and II-C
Cas1 proteins. Interestingly, the Type I-E branch appears to diverge further into two distinct
sub-clusters that correspond to similar locus architectures but distinct cas genetic sequences
(Fig 2). B.moukalabense was most likely a I-C system before loss of the other cas genes because
it grouped most closely with the I-C branch. Finally, Type I-U systems appear to be the most
distantly related Cas1s, diverging very early from the other Cas1 subtypes, including other
Type I systems.
Type I systems, including the I-E, I-C, and I-U subtypes, were the most commonly encoun-
tered bifidobacterial CRISPR-Cas system, occurring at a rate of 54% (26/48), consistent with
this system being also most prevalent in bacteria [13]. Ten systems were categorized as Type
I-C based on a similar gene content and layout as B. dentium (Fig 2). Visible on the Cas1 tree
(Fig 1), 12 species were split between two distinct Type I-E locus architectures: one cluster
included B. animalis subsp. animalis and the other cluster included Bifidobacterium angula-
tum, with the main differentiating feature being the sequence of the cas genes, including the
signature cas3 and the universal cas1 gene (Fig 2). Type I-U systems are very unique in that
they contain a cas4/cas1 fusion gene. Three of the Type I-U systems matched this typical gene
layout, as seen in Bifidobacterium thermophilum, whereas B. animalis subsp. lactis appears to
have undergone a unique genomic rearrangement event of its Type I-U CRISPR-Cas system
causing a reversed orientation of all relevant genes, thereby constituting a unique layout.
Type II systems, which are fairly rare in nature only occurring in 5% of bacteria [38], occur
at a much higher frequency in the genus Bifidobacterium; Type II systems were found in six of
the 48 genomes analyzed (12.5%), with two Type II-A systems and four Type II-C. The II-A
cas9’s canonical arrangement and content are longer than the II-C cas9s; the II-A B.merycicum
cas9 is approximately 900 nucleotides longer than the Type II-C cas9 in B. bombi. The pre-
dicted tracrRNA is located between cas9 and cas1 on the minus strand in B.merycicum, while
the tracrRNA in B. bombi, a II-C system, is upstream of the 5’ end of cas9 on the positive
strand.
The size of the repeat-spacer arrays found in bifidobacteria is highly diverse, and ranging
from 2 to 171 spacers (Fig 3, Table 1). Type I-E systems average 80 spacers per locus with some
loci encoding as many as 171 unique genetic immunization events. Type I-C systems are, on
average, smaller than Type I-E, averaging 50 spacers per locus, but can reach as many as 155
spacers. Type I-U systems average 19 spacers per locus with a range of 6 to 52 spacers. The
identified bifidobacterial Type II-C systems contain, on average, the smallest repeat-spacer
arrays (14 spacers). Because each unique spacer is acquired from invasive foreign genetic ele-
ments like phages and plasmids, we hypothesize that Type I-E systems are the most active loci
CRISPR and Bifidobacteria
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as evidenced by their large size and highest rate of occurrence in the genomes. Such large
arrays found in bifidobacteria also suggest these bacteria live in an environment rich in
Fig 1. Clustering of Cas1 into distinct phylogenetic groups.Cas1 protein sequences were aligned using the MUSCLE algorithm and used to generate a
UPMGA tree to show the divergence of different CRISPR-Cas systems. The system type and sub-type is noted on the right. The (*) indicates B.
moukalabense which contained an “Undetermined” CRISPR-Cas system.
doi:10.1371/journal.pone.0133661.g001
CRISPR and Bifidobacteria
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exogenic DNA requiring the need for an active defense system. Furthermore, such large
repeat-spacer arrays could provide a locus with high genotyping potential. The hypervariable
spacer sequences can be used to infer strain divergence and ecological relationships between
different strains [7, 39].
CRISPR spacer homology to prophage sequences
By investigating the foreign DNA source each spacer targets, insights can be gained as to the
functional role of CRISPR-Cas systems. A protospacer is the DNA sequence homolog in a
phage, plasmid, or chromosomal DNA that matches the spacer sequence stored in a CRISPR
locus. Several matches to publically available metagenomic data and matches to prophage
sequences in a local Bifidobacterium database (S1 Table), reveal that spacers in different
genomes have homology to predicted (pro)phage genomes indicating bifidobacteria have
acquired immunity against such (pro)phages (Fig 4).
The availability of 48 genome sequences of recognized bifidobacterial taxa [23, 29], allowed
the identification of bifidobacterial prophage protospacers matching the spacer sequences of
CRISPR loci identified in this study. Furthermore, as shown in S1 Table, investigation of flank-
ing regions displaying a DNA similarity with the spacer sequences greater than 91% (e-value
less that 0.0001), allowed us to precisely map their homologous region within the prophage
regions identified in these bifidobacterial genomes.
The genomes of B. angulatum, B. adolescentis and Bifidobacterium minimum contain the
most spacer sequences that target predicted prophages in bifidobacterial genomes (Fig 4).
B. angulatum possesses 26 distinct spacers that target presumed prophage sequences in 11
different Bifidobacterium species. Conversely, the prophage sequences harbored in the
genomes of Bifidobacterium stercoris and B.moukalabense taxa are potential targets of 14 and
13 CRISPR spacers, respectively. CRISPR systems that were shown to contain more than 10
spacers matching prophages in other genomes, did not contain prophages targeted by any
other CRISPR systems. Conversely, genomes without CRISPR-Cas systems or that contained
apparently degenerated CRISPR-Cas systems were more likely to have prophages that were tar-
geted by other CRISPR systems. We speculate that one reason prophages may have been able
to integrate into host chromosomes is the lack of an interfering CRISPR-Cas system. There is a
Fig 2. CRISPR-Cas locus architecture.One representative for each unique CRISPR subtypes represents the locus architecture of cas genes, CRISPR
repeats, spacers and other system-specific components (e.g. tracrRNA). The signature gene for each subtype is colored in red (cas3 or cas9 for Type I and II,
respectively). The universal cas1 and cas2 genes are colored in blue. Accessory genes are grey. The tracrRNA for Type II systems is shown in yellow. The
direction of the arrows indicates directionality of the coding sequences. The repeat-spacer array only shows the CRISPR repeats (black rectangles). Each
operon is shown at a scale of 11,000 base pairs. Long repeat-spacer arrays were shortened for simplicity indicated by a double line break. Numbers under
the arrays indicate the first and last spacer location, showing the size of the array.
doi:10.1371/journal.pone.0133661.g002
CRISPR and Bifidobacteria
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correlation between genomes targeted by CRISPR spacers and absence of functional cas genes.
However, no one type of CRISPR-Cas systems was correlated with higher numbers of spacers
targeting prophages.
CRISPR-Cas systems defined as “undetermined” and degenerate rarely had spacer
sequences that target prophages; only B. longum subsp. suis had four spacer sequences that
showed homology to prophage sequences (Fig 4). Of the 32 characterized and putative func-
tional CRISPR-Cas systems in the genus Bifidobacterium, 25 had at least one spacer sequence
that targeted a prophage. The most frequently targeted prophage-containing species are B.
longum subsp. suis, Bifidobacterium catenulatum and Bifidobacterium mongoliense which
range from 11 to 12 protospacer targets in their prophage regions (Fig 4). Interestingly, Bifido-
bacterium actinocoloniiforme and Bifidobacterium cuniculi display some spacer matches
against their own prophage sequences and none against other bifidobacterial taxa. Self-target-
ing spacers suggest that those CRISPR-Cas systems may be inactive to prevent Cas protein
cleavage of the chromosome, as self-targeting is known to be a lethal event [40].
Fig 3. CRISPR repeat-spacer array size distribution. The graph shows the variability in size of the repeat-
spacer arrays using number of spacers in each array, from Table 1. The error bars show the range of the
locus size.
doi:10.1371/journal.pone.0133661.g003
CRISPR and Bifidobacteria
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Characterization of Type II CRISPR-Cas elements
To fully characterize the Type II CRISPR-Cas systems in three Bifidobacterium genomes, we
identified the tracrRNA sequence, predicted the structure of the crRNA:tracrRNA duplex, and
investigated the PAM sequence targeted by Cas9 by identifying protospacers for the spacer
sequences in these genomes (Figs 5 and 6, S1 Table). Three representative organisms were
selected for further characterization: B.merycicum and B. bifidum which contain Type II-A
systems and B. bombi which contains a II-C system.
The tracrRNAs predicted for the three organisms are all congruent with conserved
tracrRNA: crRNA structures as previously published in the literature [36, 38], and contain a
double stemmed nexus previously only seen in lactobacilli. Combining preliminary RNASeq
analyses (S1 Text) and predicting RNase III processing sites as defined by Pertzev and Nichol-
son, the boundaries of the crRNA suggest that the 5’ processing site occurs either just below the
Fig 4. Prophage targeting by CRISPR spacers. The heat map displays BifidobacteriumCRISPR spacers that target prophage sequences harbored in
bifidobacterial genomes. The horizontal axis lists hosts that contain prophages that are targeted by CRISPR spacers. The vertical axis lists strains containing
CRISPR spacers that target a bifibacterial prophage sequence. The color intensity represents the number of cross-targeting events with red squares being
high density (up to 10 targeting events), and white squares being single targeting events. The darker pink squares correlate with higher cross-targeting
events and lighter pink squares correlate with fewer events. Blue squares represent that absence of CRISPR targeting. Hits shown in grey indicate self-
targeting spacers that target prophage sequences in that particular chromosome meaning both the spacer and the prophage target are in the same
chromosome. The darker grey indicates four distinct spacers that target prophage sequences, while the lighter grey indicates a single self-targeting spacer.
doi:10.1371/journal.pone.0133661.g004
CRISPR and Bifidobacteria
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bulge at the top of the lower stem, or after the first nucleotide of the upper stem, in the crRNA:
tracrRNA modules previously defined by Briner et al., 2014 [36, 41, 42] (Figs 5 and 6, S1 Fig).
For both II-A systems, B. bifidum and B.merycicum, the crRNA:tracrRNA duplexes appear to
have one processing site in the middle of the upper stem and a second processing site one to
two nucleotides after the bulge; these similar processing sites are likely due to similarity of
crRNA and tracrRNA sequences [36, 41, 42].
Boundaries for the crRNA and tracrRNA molecules are important for characterizing how
Type II CRISPR-Cas systems function, but the protospacer adjacent motif (PAM) is another
element that is important for functionality; the PAM is a recognition motif used by the Cas
proteins to bind foreign DNA (Fig 5) [10–11,43]. In Type II-A systems, Cas9 first binds to the
PAM and then interrogates the DNA from 3’ to 5’ [44]. The PAM identified for B.merycicum,
5’-NGG-3’, is the same as the well-characterized Streptococus pyogenes PAM, and flanks the 3’
edge of the protospacer (Figs 4 and 5, S1 Table). Interestingly, the PAM identified for B. bombi,
a Type II-C system, is predicted to be a single nucleotide 5’-NNG-3’ flanking the 3’ end of pro-
tospacers. Altogether, using the PAM, tracrRNA, CRISPR repeat, and novel Cas9, Type II
systems can be exploited to develop new genome editing tools [17, 19].
Discussion
Bifidobacteria have very frequent, diverse and large CRISPR-Cas systems. The large repeat-
spacer arrays provide a hypervariable, yet conserved, loci that can be used for genotyping
strains. Such large and diverse CRISPR-Cas loci indicate these systems are likely active and
important in bifidobacterial survival and evolutionary relatedness. While we were able to dis-
tinguish five unique subtypes of CRISPR-Cas systems in Bifidobacterium, a previous study by
Horvath et al. comparing CRISPR-Cas systems in lactic acid bacteria proposed the genus only
spanned three distinct subtypes [45]. By using a larger data set, we were able to show that the
CRISPR systems in Bifidobacterium are more diverse than previously reported and include
Type I-U and II-A systems that had previously not been identified in bifidobacteria. Surpris-
ingly, the strain of B. longum used in the Hovarth et al. study contained a Type II-C system,
but among the three subspecies of B. longum used in this study (B. longum subsp. infantis, B.
Fig 5. WebLogo predictions of PAMs. The height of each letter represents the conservation of that
nucleotide at each position in the 10nt flank at the 3’ end of the protospacer. Hits from S1 Table were used to
generate theseWebLogos.
doi:10.1371/journal.pone.0133661.g005
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longum subsp. longum, and B. longum subsp. suis), only a remnant of a CRISPR-Cas system
was detected in B. longum subsp suis [45]. This finding suggests that the presence of CRISPR-
Cas systems in Bifidobacteriummay be strain- rather than species-dependent, complicating
estimations of the exact prevalence of these systems across the entire genus.
Spacer sequences that showed positive matches to various phage and prophage DNA in
genomic and metagenomic data suggest that Bifidobacterium live in (pro)phage-rich environ-
ments and require defense systems capable of adapting to predation from phages. Interestingly,
there was a correlation between the presence of CRISPR-Cas system and the number of
CRISPR spacers that were able to target prophage sequences in other Bifidobacterium genomes.
Some bifidobacteria strains display a high number of protospacer matches to other bifidobac-
terial-specific prophages integrated in the genomes of other Bifidobacterium species. In this
context, B. angulatum has 10 CRISPR spacers matching B. catenulatum prophages, B. dentium
has six spacers that target B.moukalabense prophages, and B.minimum has nine spacers that
Fig 6. crRNA:tracrRNA duplex binds with target DNA sequence next to PAM sequence. Type II
elements involved in Cas9 targeting and cleavage for B. bombi (A), B. bifidum (B), and B.merycicum (C)
include the target protospacer (blue), the recognition PAM (purple), crRNA (green), and tracrRNA (red). The
tracrRNA:crRNA duplex come together and induce endonucleolytic activity of Cas9 to cleave foreign DNA.
The PAMwas not able to be determined for B. bifidum, so the PAM region on the target DNA strand is shown
instead. The RNaseIII processing sites were inferred from the preliminary RNASeq data and previous
characterization of RNaseIII activity [41, 42]; the darkest arrow is most likely the primary processing site and
the lighter arrows are the secondary and tertiary processing sites. For B. bombi, the processing sites were
based on the boundaries determined for the crRNAs using the RNASeq data. For B. bifidum, the processing
sites were determined using the boundaries from the tracrRNA RNASeq data. The B.merycicum sites are
based on the boundaries from the B. bifidum data; the tracrRNA sequences only differed by five nucleotides
in the upperstem-bulge-lowerstem region, meaning the processing sites are likely similar.
doi:10.1371/journal.pone.0133661.g006
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target B.mongoliense. Such findings might be explained by these organisms inhabiting same
ecological niches followed by co-evolution with a similar repertoire of phages. Futhermore, as
described in the recent work aimed to reassess the bifidobacterial taxonomy [29], B. dentium
and B.moukalabense are two of the eight bifidobacterial species fitting in the B. adolescentis
group. The identification of those shared spacer sequence targets further supports close evolu-
tionary development of these two genomes and may suggest CRISPR spacer conferred pro-
phage exclusion that differentiated the Bifidobacterium genus [29].
Preliminary transcriptome data suggests some of these systems are actively being tran-
scribed and maintained, supporting the hypothesis that attack from (pro)phages is an ever-
present threat to Bifidobacterium. This machinery that naturally targets foreign DNA from
Type II CRISPR-Cas systems can be exploited to create new tools for genome editing and
engineering. B. bombimay be an intriguing new prospect for development of new tools as the
predicted PAM is only a single nucleotide and the Cas9 protein (1239 amino acids) is 129
amino acid residues smaller than the widespread S. pyogenes Cas9 (1368 amino acids) [19].
Altogether, the bifidobacterial CRISPR-Cas systems constitute a framework for various
potential biotechnological and ecological uses. The frequent prevalence of large and diverse
CRISPR loci provides a platform for strain genotyping and differential evolutionary studies.
CRISPR spacer sequences can help provide insights into historical phage-host interplay as well
as broaden our understanding of phage resistance in Bifidobacterium. The characterization of
Type II elements in a select set of bifidobacteria may also open the door for next generation
molecular tools for genome editing in bacteria and potentially eukaryotes.
Supporting Information
S1 Fig. Locus transcriptional profiles. (A) small RNA molecules from B. bombi that mapped
to the CRISPR repeat-spacer array. (B) boundaries of spacer ten, the most highly transcribed
spacer in the B. bombi CRISPR repeat-spacer array. Other show RNA reads that mapped to the
CRISPR-Cas system in B. bifidum. (C) transcripts mapped to the entire locus suggesting this
system is transcribed. (D) transcripts that map to the tracrRNA sequence; the 5’ boundaries for
this molecule can be determined.
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RNA sequences.
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